Clinical Trial Update: A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating RAD011 (cannabidiol oral solution) for Prader-Willi Syndrome has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• RAD011 (cannabidiol)

Snippet

Sponsor: Radius Pharmaceuticals, Inc. | Conditions: Prader-Willi Syndrome | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2023-10-19